Kazan State Medical University

Running trials

• Recruiting

  Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course and Prognosis

  NCT07375433· National Medical Research Center for Therapy and Preventive Medicine· Source

• Active, not recruiting

  A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

  NCT04175600· Phase 3· Actelion· Source

• Active, not recruiting

  Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

  NCT04006210· Phase 3· NeuroDerm Ltd.· Source

• Recruiting

  The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.

  NCT03945968· Russian Federation of Anesthesiologists and Reanimatologists· Source

• Active, not recruiting

  A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

  NCT03675308· Phase 3· AbbVie· Source

• Active, not recruiting

  A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

  NCT03492177· Phase 2· Actelion· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

  NCT03519945· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

  NCT03345823· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

  NCT03006068· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

  NCT02629159· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD2 recruiting
• Heart failure2 recruiting
• Alzheimer disease1 recruiting
• Asthma1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Epilepsy1 recruiting
• Parkinson disease1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT04673357· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT04630028· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

  NCT04169373· Phase 3· AbbVie· Source

• Completed

  Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

  NCT04029480· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Shire· Source

• Completed

  A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

  NCT03104400· Phase 3· AbbVie· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Takeda· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Sarcoidosis10 works · 0 trials
• Dystonia6 works · 0 trials
• Familial hypercholesterolaemia5 works · 0 trials
• Irritable bowel syndrome5 works · 0 trials